News | November 04, 2022
Sanofi India posts Q3CY22 net profit at Rs. 130.9 Cr
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
The laboratory is equipped to perform high-volume diagnostic testing services
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
His experience covers a wide range of areas including advisory services in the field of accounting, taxation, corporate and commercial laws, and regulatory matters
The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Subscribe To Our Newsletter & Stay Updated
